Marksans Pharma Q3 FY26 results: consolidated PAT up 35 percent YoY
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma posted strong Q3 FY26 results. Consolidated revenue grew 14 percent YoY to about Rs 7,758 million and PAT jumped 35 percent to about Rs 714 million. For 9M FY26, revenue rose 15 percent to about Rs 20,940 million and PAT climbed 37 percent to about Rs 1,711 million. Standalone Q3 PAT surged 144 percent to about Rs 501 million. The company also formed two new wholly owned subsidiaries in Ireland and Canada in January 2026. Auditor M S K A converted to LLP format, the firm remains the same.
Strong earnings growth with consolidated PAT up 35 percent YoY in Q3 and 37 percent for 9M FY26, reflecting healthy momentum. New subsidiaries signal expansion.